Values First Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Values First Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-36,032	Closed	-$109K	–	237
2024 Q4	$109K	Sell	36,032 -38,497	-52%	-$126K	0.06%	188
2024 Q3	$274K	Sell	74,529 -396	-0.5%	-$1.44K	0.15%	128
2024 Q2	$306K	Buy	74,925 +3,859	+5%	+$43.1K	0.18%	122
2024 Q1	$1.12M	Buy	71,066 +22,998	+48%	+$316K	0.66%	46
2023 Q4	$728K	Buy	48,068 +7,148	+17%	+$104K	0.44%	76
2023 Q3	$821K	Buy	40,920 +10,362	+34%	+$263K	0.53%	59
2023 Q2	$862K	Buy	30,558 +22,922	+300%	+$550K	0.52%	58
2023 Q1	$131K	Buy	+7,636	New	+$155K	0.08%	155
2022 Q1	–	Sell	-2,542	Closed	-$214K	–	180
2021 Q4	$214K	Buy	+2,542	New	+$197K	0.13%	154

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Values First Advisors's ZNTL Position: Q1 2025 in Review

Values First Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 36,032 shares — an estimated $109K sold.

Values First Advisors first reported a position in ZNTL in Q4 2021 and held it in 9 quarters. The position peaked at $1.12M in Q1 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

Values First Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Values First Advisors sold 36,032 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $109K.
Values First Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Values First Advisors's Zentalis Pharmaceuticals position peaked at $1.12M in Q1 2024.
132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Values First Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.